Search

Your search keyword '"Open-angle glaucoma -- Drug therapy"' showing total 6 results
Start Over Descriptor "Open-angle glaucoma -- Drug therapy" Topic drug approval
6 results on '"Open-angle glaucoma -- Drug therapy"'

1. Omlonti Approved for Open-Angle Glaucoma, Ocular Hypertension

Author

Park, Brian

Subjects
United States. Food and Drug Administration, Ophthalmic drugs, Drug approval, Open-angle glaucoma -- Drug therapy, Hypertension -- Drug therapy, Health
Abstract

The Food and Drug Administration (FDA) has approved Omlonti[sup.®] (omidenepag isopropyl ophthalmic solution) 0.002% for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular [...]

Published
2022

2. Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan[TM] (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension

Subjects
United States. Food and Drug Administration, Prostaglandins, Ophthalmic drugs, Drug approval, Open-angle glaucoma -- Drug therapy, Hypertension -- Drug therapy, Business, Business, international, Rhopressa (Medication), Rocklatan (Medication)
Abstract

- First and Only Once-Daily, Fixed-Dose Combination of a Prostaglandin Analog and a Rho Kinase (ROCK) Inhibitor - - Rocklatan[TM] Demonstrated Statistical Superiority over Widely-Prescribed First-Line Agent Latanoprost - DURHAM, [...]

Published
2019

3. Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa[R] (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension

Subjects
United States. Food and Drug Administration, Ophthalmic agents, Hypertension -- Drug therapy, Drug approval, Open-angle glaucoma -- Drug therapy, Business, Business, international
Abstract

Product Approved Ahead of the Scheduled PDUFA Date of February 28, 2018 IRVINE, Calif. -- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the [...]

Published
2017

4. Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan[TM] netarsudil and latanoprost ophthalmic solution 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension

Subjects
United States. Food and Drug Administration, Latanoprost, Ophthalmic agents, Netarsudil, Hypertension -- Drug therapy, Open-angle glaucoma -- Drug therapy, Drug approval, Backup software, Pharmaceutical industry, Retinal diseases, Technology, Editors, Health, Health care industry, Rhopressa (Medication), Rocklatan (Medication)
Abstract

2019 MAR 31 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical [...]

Published
2019

5. Aerie Pharmaceuticals Receives US FDA Approval of Rocklatan 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension

Subjects
United States. Food and Drug Administration, Ophthalmic agents, Netarsudil, Hypertension -- Drug therapy, Open-angle glaucoma -- Drug therapy, Drug approval, Pharmaceutical industry, Latanoprost, Prostaglandins, Chemistry, Rhopressa (Medication)
Abstract

M2 PHARMA-March 14, 2019-Aerie Pharmaceuticals Receives US FDA Approval of Rocklatan 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension (C)2019 M2 COMMUNICATIONS - [...]

Published
2019

6. Sucampo Pharmaceuticals Inc wins FDA approval for RESCULA for lowering intraocular pressure in open-angle glaucoma patients

Subjects
United States. Food and Drug Administration, Sucampo Pharmaceuticals Inc., Drug approval, Open-angle glaucoma -- Drug therapy, Pharmaceutical industry, Chemistry, Rescula (Medication) -- Labeling
Abstract

M2 PHARMA-December 13, 2012-Sucampo Pharmaceuticals Inc wins FDA approval for RESCULA for lowering intraocular pressure in open-angle glaucoma patients(C)2012 M2 COMMUNICATIONS Pharmaceutical company Sucampo Pharmaceuticals Inc (NasdaqGM:SCMP) reported on Wednesday [...]

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results